Conversely, PIK3CA mutations, which are commonly observed in HR+ tumours and serve as therapeutic targets in many settings, were less frequent Although less prevalent than TNBC, HR+/HER2− tumours in African cohorts exhibited a high burden of structural variants alongside pronounced homologous-recombination-deficiency (HRD) signatures. The gene discussed is PIK3CA; the disease is neoplasm.